n-3 fatty acids and cardiovascular outcomes in dysglycemia

New England Journal of Medicine

Volumn 367, Issue 18, 2012, Pages 1760-1761

  Levy, Yishai ^a  

^a Rambam Health Care Campus ^*  (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; LONG ACTING INSULIN; OMEGA 3 FATTY ACID;

CARDIOVASCULAR DISEASE; FEMALE; GLUCOSE INTOLERANCE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, OMEGA-3; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE;

EID: 84868235677     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1210552     Document Type: Letter

References (6)

1. The ORIGIN Trial Investigators. n-3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-18.
2. Guallar E, Aro A, Jiménez FJ, et al. Omega-3 fatty acids in adipose tissue and risk of myocardial infarction: the EURAMIC study. Arterioscler Thromb Vasc Biol 1999;19:1111-8.
3. Kardinaal AF, Aro A, Kark JD, et al. Association between beta-carotene and acute myocardial infarction depends on poly-unsaturated fatty acid status. Arterioscler Thromb Vasc Biol 1995;15:726-32.
4. Dubnov G, Berry EM. Omega-6/omega-3 fatty acid ratio: the Israeli paradox. World Rev Nutr Diet 2003;92:81-91.
5. Cohen G, Riahi Y, Sasson S. Lipid peroxidation of poly-unsaturated fatty acids in normal and obese adipose tissues. Arch Physiol Biochem 2011;117:131-9.
6. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011;58:2047-67.